Skip to main content
Premium Trial:

Request an Annual Quote

Diaceutics, London Genetics to Co-Develop Software to Support Biomarker Research Collaborations


Personalized medicine consultancy Diaceutics is partnering with pharmacogenomics service provider London Genetics to develop software tools that will help biopharmaceutical companies access data and samples from academic biomarker research groups, the companies said today.

The new software, which the firms plan to launch next year, is based on the Diaceutics Fusion platform, a personalized medicine planning application designed for targeted therapy development teams, and the London Genetics Biomarker Pathway platform.

The companies said that the new software will allow research teams to build biomarker hypotheses, request expressions of interest for patient samples, and prepare proposals for clinical development.

Expressions of interest for access to patient samples will be sent to academic biomarker research teams, including London Genetics’ network of more than 3,000 investigators.

"The new tools will enable commercial biomarker research teams to comprehensively explore global biomarker resources to identify genes and gene sequences, as well as the researchers and clinicians relevant to their targeted therapy research," the companies said.

“Biomarker research is often limited because teams don’t know the capabilities of external research centers and miss potential collaborations which could accelerate their targeted therapy development,” Peter Keeling, CEO of Diaceutics, said in a statement.